East Resources Acquisition Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ERESW research report →
Price Chart
Get TickerSpark's AI analysis on ERESW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- 28.46
- PEG
- 0.03
- P/S
- 2.99
- P/B
- 1.83
- EV/EBITDA
- 11.07
- Div Yield
- 2.40%
- Gross Margin
- 68.55%
- Op Margin
- 31.17%
- Net Margin
- 10.55%
- ROE
- 6.56%
- ROIC
- 5.97%
Latest fiscal year · YoY change
- Revenue
- $235.24M+110.2%
- Gross Profit
- $169.17M+68.2%
- Op Income
- $87.05M
- Net Income
- $36.53M+252.4%
- EPS
- $0.38+211.8%
- OCF Growth
- +87.7%
- FCF Growth
- +87.3%
- 52W High
- $0.30
- 52W Low
- $0.23
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.00
- RSI (14)
- 60
- Avg Volume
- 0
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Abacus Global Management posted strong Q2 2026 growth, beat its guidance, and highlighted accelerating fee-based and technology initiatives tied to LifeARC, the new interval fund, and Manning & Napier.· August 6, 2026
- Revenue rose 30% year over year to $73 million, with adjusted net income of $27.1 million and adjusted EPS of $0.28, both above prior guidance.
- Adjusted EBITDA was $40 million, up 27% year over year, with a 55% margin; adjusted ROE was 25%.
- Longevity funds raised $544.2 million in the first half, above the $500 million target, and $256.1 million in Q2 alone.
- The ABX Longevity Growth and Income Fund launched after SEC effectiveness, and management said it expects assets to start coming in during Q3.
- Management expects Q3 adjusted net income of $26 million to $28 million and full-year adjusted net income of $100 million to $106 million, while staying conservative on the annual outlook.
Q2 revenue was $73 million, up 30% year over year. Adjusted net income was $27.1 million, or $0.28 per diluted share, above guidance of $24 million to $26 million and $0.24 to $0.26 per share. Adjusted EBITDA was $40 million, up 27% year over year, with a 55% margin; adjusted ROE was 25%, up 400 basis points year over year. Total operating expense was $42.5 million, cash ended at $23.4 million, policy assets were $383 million, and long-term debt was $290.8 million. For Q3, management guided to adjusted net income of $26 million to $28 million and adjusted EPS of $0.26 to $0.28. For full-year 2026, it reiterated adjusted net income of $100 million to $106 million and adjusted EPS of $1.00 to $1.05.
Jay Jackson framed the quarter around a broader long-term strategy: building an infrastructure for “lifespan-linked finance” using LifeARC, the company’s longevity data platform. He emphasized the $124 trillion wealth transfer opportunity, said Abacus is positioned to be the “intelligence layer” for lifespan-linked finance, and highlighted the launch of the ABX interval fund and early tokenization work as signs the strategy is moving from concept to execution. His tone was highly confident and expansionary, with repeated comments that the company has visibility into growth and is still early in a much larger opportunity.
Bill McCauley focused on operating execution and financial discipline. He said capital deployed was close to $200 million in Q2, bringing year-to-date deployment to $362 million, and noted revenue of $73 million, adjusted net income of $27.1 million, adjusted EBITDA of $40 million, and a 55% margin. He also highlighted $256.1 million of second-quarter inflows into longevity funds, $6.5 million of management and servicing fees across those funds, cash of $23.4 million, policy assets of $383 million, and debt of $290.8 million. On guidance, he reiterated the full-year targets and explained that adjusted net income guidance is still presented on a gross basis, with an approximate 25% tax bridge to net equivalents.
Analysts pressed management on why full-year guidance was unchanged after a Q2 beat and a higher Q3 outlook; Jay Jackson said the company is simply being conservative and still expects to land near the top end of the annual range, implying a stronger Q4. Questions also focused on the new interval fund, where management said it has already engaged custodians, large RIAs, pension clients, and other distribution partners, and expects assets to come in during Q3 with a potentially strong Q4. Analysts asked about capital deployment, LifeARC monetization, the lower-than-expected asset management revenue, and the dividend; management attributed the revenue softness to ETF outflows, said LifeARC will likely be monetized via a recurring rev-share model, and said the annual dividend should increase in 2026 if current trends hold.
The bull case from the call is that Abacus is showing both operational momentum and product expansion at the same time. Q2 beat guidance, longevity-fund inflows exceeded the company’s target, the interval fund is live, and management said early Manning & Napier integration results are already producing referrals, client conversions, and policy sourcing. Management was also upbeat that LifeARC, tokenization, and additional distribution relationships could expand recurring revenue and fee-paying AUM over time.
The main risks discussed were dependence on ETF-related asset management fees, which management said weighed on Q2 revenue, and the fact that LifeARC and the interval fund are still very early in monetization. The company also acknowledged that Q2 tax expense was higher than usual, though it expects normalization, and that capital deployment can be seasonal and tied to capital inflows and securitization timing. More broadly, management’s large growth ambitions depend on continued adoption of new products and partnerships rather than just the legacy business.
AI summary of the company's earnings call · Paraphrased · Not investment advice
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 23, 26 | Ganovsky Matthew | sell | 22,800 |
| Sep 23, 26 | Kirby Kevin Scott | sell | 22,745 |
| Sep 23, 26 | McNealy Sean | sell | 22,700 |
| Sep 18, 26 | McNealy Sean | sell | 24,000 |
| Sep 21, 26 | McNealy Sean | sell | 35,854 |
| Sep 22, 26 | McNealy Sean | sell | 21,100 |
| Sep 18, 26 | Kirby Kevin Scott | sell | 24,000 |
| Sep 21, 26 | Kirby Kevin Scott | sell | 36,400 |
| Sep 22, 26 | Kirby Kevin Scott | sell | 21,100 |
| Sep 18, 26 | Ganovsky Matthew | sell | 24,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ERESW coverage
Recent articles, reports, and earnings notes.
No research on ERESW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ERESW report →